Kinase-Independent Functions of MASTL in Cancer: A New Perspective on MASTL Targeting.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
06 07 2020
Historique:
received: 01 06 2020
revised: 29 06 2020
accepted: 01 07 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 13 4 2021
Statut: epublish

Résumé

Microtubule-associated serine/threonine kinase-like (MASTL; Greatwall) is a well-characterized kinase, whose catalytic role has been extensively studied in relation to cell-cycle acceleration. Importantly, MASTL has been implicated to play a substantial role in cancer progression and subsequent studies have shown that MASTL is a significant regulator of the cellular actomyosin cytoskeleton. Several kinases have non-catalytic properties, which are essential or even sufficient for their functions. Likewise, MASTL functions have been attributed both to kinase-dependent phosphorylation of downstream substrates, but also to kinase-independent regulation of the actomyosin contractile machinery. In this review, we aimed to highlight the catalytic and non-catalytic roles of MASTL in proliferation, migration, and invasion. Further, we discussed the implications of this dual role for therapeutic design.

Identifiants

pubmed: 32640605
pii: cells9071624
doi: 10.3390/cells9071624
pmc: PMC7407770
pii:
doi:

Substances chimiques

Actins 0
Microtubule-Associated Proteins 0
MASTL protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Biochem Cell Biol. 2010 Oct;42(10):1622-33
pubmed: 20412868
Cell Cycle. 2010 Sep 1;9(17):3591-601
pubmed: 20818157
J Biol Chem. 2004 Oct 22;279(43):44756-62
pubmed: 15308673
Mol Cell. 2006 Apr 7;22(1):83-91
pubmed: 16600872
Protein Sci. 2018 Jan;27(1):233-244
pubmed: 28940711
Trends Cell Biol. 2009 Apr;19(4):174-9
pubmed: 19285869
Exp Hematol. 2009 Aug;37(8):901-8
pubmed: 19460416
Hybridoma (Larchmt). 2011 Oct;30(5):469-74
pubmed: 22008075
Onco Targets Ther. 2017 Feb 20;10:711-724
pubmed: 28260916
Science. 2010 Dec 17;330(6011):1670-3
pubmed: 21164013
J Cell Sci. 2018 Oct 24;131(20):
pubmed: 30355803
Mol Cancer. 2018 Aug 1;17(1):111
pubmed: 30068336
Cell Cycle. 2013 Jun 1;12(11):1762-72
pubmed: 23656782
Sci Rep. 2018 Mar 20;8(1):4894
pubmed: 29559668
Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22
pubmed: 20027184
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Cell Commun Signal. 2011 Oct 28;9(1):23
pubmed: 22035226
Cancer Lett. 2016 Feb 1;371(1):79-89
pubmed: 26616283
Trends Cell Biol. 2008 May;18(5):210-9
pubmed: 18394899
Neuro Oncol. 2013 May;15(5):578-88
pubmed: 23416699
Elife. 2014 Mar 11;3:e01695
pubmed: 24618897
Oncotarget. 2016 Nov 1;7(44):71182-71197
pubmed: 27563826
Front Cell Dev Biol. 2018 Nov 23;6:162
pubmed: 30555827
Dev Cell. 2007 May;12(5):699-712
pubmed: 17488622
Nature. 2020 Apr;580(7805):663-668
pubmed: 32152607
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17374-9
pubmed: 24101512
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9529-34
pubmed: 15976019
J Cell Biol. 2019 Feb 4;218(2):541-558
pubmed: 30626720
Curr Biol. 2017 Nov 6;27(21):3350-3358.e3
pubmed: 29107549
Cell Cycle. 2019 May;18(10):1154-1167
pubmed: 31072185
Elife. 2015 Nov 27;4:
pubmed: 26613407
R Soc Open Sci. 2018 Dec 5;5(12):181006
pubmed: 30662724
Mol Cell Biol. 2012 Apr;32(8):1337-53
pubmed: 22354989
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Cell Death Differ. 2018 May;25(5):828-840
pubmed: 29229993
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12564-9
pubmed: 20538976
Oncol Lett. 2017 Dec;14(6):7283-7287
pubmed: 29344164
J Clin Invest. 2018 Dec 3;128(12):5351-5367
pubmed: 30252678
Nat Cell Biol. 2015 Feb;17(2):148-59
pubmed: 25621953
Trends Cell Biol. 2017 Jan;27(1):26-41
pubmed: 27528558
Am J Physiol Cell Physiol. 2013 Jan 15;304(2):C115-27
pubmed: 23054059
Oncogene. 2018 Aug;37(33):4518-4533
pubmed: 29743597
Science. 2010 Dec 17;330(6011):1673-7
pubmed: 21164014
J Cell Biol. 2020 Jun 1;219(6):
pubmed: 32311005
J Cell Biol. 2004 Feb 16;164(4):487-92
pubmed: 14970188
Oncotarget. 2014 Nov 30;5(22):11479-89
pubmed: 25373736
Mol Cell Proteomics. 2020 Feb;19(2):326-343
pubmed: 31852836
Development. 2013 Aug;140(15):3079-93
pubmed: 23861057
J Natl Cancer Inst. 2013 Mar 20;105(6):393-404
pubmed: 23355761

Auteurs

James Ronald William Conway (JRW)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Elisa Närvä (E)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Maria Emilia Taskinen (ME)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Johanna Ivaska (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.
Department of Biochemistry, University of Turku, 20520 Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH